Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Last traded Sep 3, 2025. This price is not current.
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
Dated clinical, regulatory and corporate events for COSCIENS Biopharma Inc.
How CSCI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-09-30 | Avenanthramides Tablets | Phase 2 data readout | Phase 2 |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Macimorelin Small MoleculesCompletedNCT04786873 | Growth Hormone Deficiency | Phase 3 | COMPLETED | 101 | Jun 13, 2024 |
Readouts, endpoints and source filings for every CSCI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| avenanthramides | inflammation | Phase 1/2a | 2025-03-13 | No significant adverse events were reported during the Phase 1 portion of the AvenActive study. A total of 72 healthy subjects have completed the Phase 1 portion of the AvenActive study which included 48 healthy subjects in a single ascending dose (SAD) arms and 24 healthy subjects in multiple ascending dose (MAD) arms. Subjects received doses ranging from 30 mg to 960 mg per group per day.Read More | COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory ProductRead More |
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CSCI for Q3 2026. | ||||
Shares sold short, counted twice a month.
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
How CSCI ranks across every disease it competes in